Detalhe da pesquisa
1.
Evaluation of genetic variants associated with the risk of thiopurine-related pancreatitis: a case control study from ENEIDA registry.
Dig Dis
; 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38452742
2.
Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors.
Clin Gastroenterol Hepatol
; 21(2): 406-414.e7, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35124272
3.
Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.
J Gastroenterol Hepatol
; 35(12): 2080-2087, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32350906
4.
Bifidobacterium longum subsp infantis CECT7210-supplemented formula reduces diarrhea in healthy infants: a randomized controlled trial.
Pediatr Res
; 83(6): 1120-1128, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29538368
5.
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients. / Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) y de la Confederación de Asociaciones de Enfermedad de Crohn y Colitis Ulcerosa (ACCU) para el manejo de los aspectos psicológicos en la enfermedad inflamatoria intestinal.
Gastroenterol Hepatol
; 41(2): 118-127, 2018 Feb.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-29275001
6.
Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
Scand J Gastroenterol
; 51(2): 186-95, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26200929
7.
Frequency, predictors, and consequences of maintenance infliximab therapy intensification in ulcerative colitis.
Rev Esp Enferm Dig
; 107(9): 527-33, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26334458
8.
Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry.
J Crohns Colitis
; 18(1): 65-74, 2024 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37522878
9.
Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients.
Inflamm Bowel Dis
; 30(2): 167-182, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37536268
10.
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry.
Therap Adv Gastroenterol
; 17: 17562848231221713, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38187926
11.
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA.
Pharmaceutics
; 16(5)2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38794292
12.
Serum Calcitonin Gene-Related Peptide α and ß Levels are Increased in COVID-19 Inpatients.
Arch Med Res
; 54(1): 56-63, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36588002
13.
Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study.
Cancers (Basel)
; 15(3)2023 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36765708
14.
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry.
J Crohns Colitis
; 17(1): 83-91, 2023 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35913456
15.
Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.
Aliment Pharmacol Ther
; 58(1): 60-70, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37089065
16.
An α-lactalbumin-enriched and symbiotic-supplemented v. a standard infant formula: a multicentre, double-blind, randomised trial.
Br J Nutr
; 107(11): 1616-22, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22079177
17.
Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy.
Therap Adv Gastroenterol
; 15: 17562848221077837, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35251307
18.
Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J. Clin. Med. 2021, 10, 2885.
J Clin Med
; 11(19)2022 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36233844
19.
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case-Control Study (COVID-19-EII).
J Clin Med
; 11(24)2022 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36556155
20.
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry.
J Clin Med
; 11(2)2022 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35054116